Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease.
Fiche publication
Date publication
octobre 2015
Journal
Alimentary pharmacology & therapeutics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Safroneeva E, Vavricka SR, Fournier N, Pittet V, Peyrin-Biroulet L, Straumann A, Rogler G, Schoepfer AM,
Lien Pubmed
Résumé
The impact of early treatment with immunomodulators (IM) and/or TNF antagonists on bowel damage in Crohn's disease (CD) patients is unknown.
Mots clés
Adalimumab, administration & dosage, Adjuvants, Immunologic, therapeutic use, Adult, Aged, Certolizumab Pegol, administration & dosage, Cohort Studies, Crohn Disease, drug therapy, Digestive System Surgical Procedures, statistics & numerical data, Early Medical Intervention, Female, Humans, Immunologic Factors, administration & dosage, Infliximab, administration & dosage, Intestines, drug effects, Male, Middle Aged, Switzerland, epidemiology, Time Factors, Tumor Necrosis Factor-alpha, antagonists & inhibitors
Référence
Aliment. Pharmacol. Ther.. 2015 Oct;42(8):977-89